Overview

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Status:
Recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are: - To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). - To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the efficacy of magrolimab in combination with R-GemOx in aspartate aminotransferase (ASCT) ineligible DLBCL participants.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Forty Seven, Inc.
Gilead Sciences

Collaborator:

The Leukemia and Lymphoma Society

Treatments:

Gemcitabine
Magrolimab
Oxaliplatin
Rituximab